BRK-B vs CNS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
CNS exhibits a stable financial foundation with a Piotroski F-Score of 5/9 and very low debt (D/E 0.22), but it is fundamentally overvalued. The current price of $67.71 trades at a significant premium to both the Graham Number ($27.35) and the growth-based Intrinsic Value ($50.59). This valuation gap is compounded by a bearish technical trend (0/100), insider selling, and a dangerously high dividend payout ratio of 83.77%. Recent earnings performance is lackluster, with only one beat in the last four quarters.
Compare Another Pair
Related Comparisons
BRK-B vs CNS: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Cohen & Steers, Inc. (CNS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.